Costa Rica to reevaluate use of hydroxychloroquine for COVID-19 treatment
“We’re just acting by precaution,” WHO emergencies chief Michael Ryan agreed.
Román Macaya, executive president of Costa Rica’s Social Security Fund (CCSS),
acknowledged the HCQ news and said Monday that the country is convening an urgent meeting of pharmaceutical experts to determine next steps.
At the same time, Macaya said Costa Rica has used hydroxychloroquine differently than what was studied by researchers, who analyzed 96,032 patients who were hospitalized with COVID-19.
In Costa Rica, all patients — including those with minor symptoms or who are asymptomatic —
are offered the option to take hydroxychloroquine upon their diagnosis, as long as they don’t have contraindications to the drug, Macaya said.
Costa Rica has a low case fatality rate (1.07%), and fewer than 5% of known active coronavirus cases are currently hospitalized.
“We can’t say that’s a result of this medication, but we can’t discard it either,” Macaya said.
The Costa Rican health system has not released data comparing the outcomes of patients treated with hydroxychloroquine to other methods.
Content embedded from external sources will not be displayed without your consent.
Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.
Content embedded from external sources will not be displayed without your consent.
Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.
Content embedded from external sources will not be displayed without your consent.
Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.
Content embedded from external sources will not be displayed without your consent.
Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.
To convince the opposition both in Scandinavia and elsewhere
Sindre is being very methodical in replicating and extending Holmlid's research
Leif Holmlid states
"
This total energy output is based on numerous experiments which measure the number of muons formed; however, the uncertainty in this number is relatively large due to the complex mixture of mesons and leptons formed by the present generator"
so definitely he would do more experiments to reduce this uncertainty... if he could ...but I think that expts won't be enough
.. expts never have been enough .. at least since Copenhagen ..
post-Bohr nuclear physics has been very political..in Scandinavia and elsewhere
The Lancet report says..basically the metaaanlysis results are inconclusive.. RCTs are required...
The meta data .. mainly from the USA is vague on medication timing
Covid-19 virus overwhelms the host defenses and causes massive inflammation coagulation quickly,
with any medication timing is critical... with Covid -19 timing is especially critical. to the hour.. not to the day
ASAP is essential..the medications has to be in the plasma before the viral numbers reach a crtical mass..
Any RCT that does not make sure of strict timing is useless..
I am sure that when the Costa Rican medics asked the Chinese medics about medication..in their video link
the advice was ASAP,, jinkuai
尽快
which the Costa Ricans did not translate as manana..or when the patient shows severe symtoms..
There are no rescue medications once the inflammatory onslaught has decimated the tissue structure
“In Costa Rica, we have been using hydroxychloroquine since we had a teleconference meeting with personnel from China, personnel from Shanghai and Wuhan,”
said Mario Ruíz, Medical Manager of the Costa Rican Social Security System (CCSS, or Caja).
“They were the ones who attended the emergency that arose in China, and hydroxychloroquine has its specifications and specific doses.
Thanks to this help provided by the Chinese scientific community and a therapeutic care manual, we are using these treatments at the established doses.”
Content embedded from external sources will not be displayed without your consent.
Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.
This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies.More DetailsClose